Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?
Cytokines are small proteins that regulate the growth and functional activity of immune cells, and several have been approved for cancer therapy. Oncolytic viruses are agents that mediate antitumor activity by directly killing tumor cells and inducing immune responses. Talimogene laherparepvec is an...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/5/e008025.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861129113239552 |
|---|---|
| author | Howard L Kaufman Hongbin Wang Dipongkor Saha Samuel D Rabkin Mia Borlongan Uyen Le Hans J Nauwynck |
| author_facet | Howard L Kaufman Hongbin Wang Dipongkor Saha Samuel D Rabkin Mia Borlongan Uyen Le Hans J Nauwynck |
| author_sort | Howard L Kaufman |
| collection | DOAJ |
| description | Cytokines are small proteins that regulate the growth and functional activity of immune cells, and several have been approved for cancer therapy. Oncolytic viruses are agents that mediate antitumor activity by directly killing tumor cells and inducing immune responses. Talimogene laherparepvec is an oncolytic herpes simplex virus type 1 (oHSV), approved for the treatment of recurrent melanoma, and the virus encodes the human cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF). A significant advantage of oncolytic viruses is the ability to deliver therapeutic payloads to the tumor site that can help drive antitumor immunity. While cytokines are especially interesting as payloads, the optimal cytokine(s) used in oncolytic viruses remains controversial. In this review, we highlight preliminary data with several cytokines and chemokines, including GM-CSF, interleukin 12, FMS-like tyrosine kinase 3 ligand, tumor necrosis factor α, interleukin 2, interleukin 15, interleukin 18, chemokine (C-C motif) ligand 2, chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 4, or their combinations, and show how these payloads can further enhance the antitumor immunity of oHSV. A better understanding of cytokine delivery by oHSV can help improve clinical benefit from oncolytic virus immunotherapy in patients with cancer. |
| format | Article |
| id | doaj-art-ae1324671e874fbf8b0558f501e18cfa |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-ae1324671e874fbf8b0558f501e18cfa2025-02-10T04:55:09ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-05-0112510.1136/jitc-2023-008025Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?Howard L Kaufman0Hongbin Wang1Dipongkor Saha2Samuel D Rabkin3Mia Borlongan4Uyen Le5Hans J Nauwynck66Ankyra Therapeutics/Massachusetts General Hospital, Boston, MA, USADepartment of Pharmaceutical and Biomedical Sciences, California Northstate University College of Pharmacy, Elk Grove, California, USADepartment of Pharmaceutical and Biomedical Sciences, California Northstate University College of Pharmacy, Elk Grove, California, USABrain Tumor Research Center, Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USACollege of Graduate Studies, California Northstate University, Elk Grove, California, USADepartment of Pharmaceutical and Biomedical Sciences, California Northstate University College of Pharmacy, Elk Grove, California, USALaboratory of Virology, Department of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Ghent University, Merelbeke, BelgiumCytokines are small proteins that regulate the growth and functional activity of immune cells, and several have been approved for cancer therapy. Oncolytic viruses are agents that mediate antitumor activity by directly killing tumor cells and inducing immune responses. Talimogene laherparepvec is an oncolytic herpes simplex virus type 1 (oHSV), approved for the treatment of recurrent melanoma, and the virus encodes the human cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF). A significant advantage of oncolytic viruses is the ability to deliver therapeutic payloads to the tumor site that can help drive antitumor immunity. While cytokines are especially interesting as payloads, the optimal cytokine(s) used in oncolytic viruses remains controversial. In this review, we highlight preliminary data with several cytokines and chemokines, including GM-CSF, interleukin 12, FMS-like tyrosine kinase 3 ligand, tumor necrosis factor α, interleukin 2, interleukin 15, interleukin 18, chemokine (C-C motif) ligand 2, chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 4, or their combinations, and show how these payloads can further enhance the antitumor immunity of oHSV. A better understanding of cytokine delivery by oHSV can help improve clinical benefit from oncolytic virus immunotherapy in patients with cancer.https://jitc.bmj.com/content/12/5/e008025.full |
| spellingShingle | Howard L Kaufman Hongbin Wang Dipongkor Saha Samuel D Rabkin Mia Borlongan Uyen Le Hans J Nauwynck Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? Journal for ImmunoTherapy of Cancer |
| title | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? |
| title_full | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? |
| title_fullStr | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? |
| title_full_unstemmed | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? |
| title_short | Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? |
| title_sort | cytokine armed oncolytic herpes simplex viruses a game changer in cancer immunotherapy |
| url | https://jitc.bmj.com/content/12/5/e008025.full |
| work_keys_str_mv | AT howardlkaufman cytokinearmedoncolyticherpessimplexvirusesagamechangerincancerimmunotherapy AT hongbinwang cytokinearmedoncolyticherpessimplexvirusesagamechangerincancerimmunotherapy AT dipongkorsaha cytokinearmedoncolyticherpessimplexvirusesagamechangerincancerimmunotherapy AT samueldrabkin cytokinearmedoncolyticherpessimplexvirusesagamechangerincancerimmunotherapy AT miaborlongan cytokinearmedoncolyticherpessimplexvirusesagamechangerincancerimmunotherapy AT uyenle cytokinearmedoncolyticherpessimplexvirusesagamechangerincancerimmunotherapy AT hansjnauwynck cytokinearmedoncolyticherpessimplexvirusesagamechangerincancerimmunotherapy |